Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections | Zendy

Paul Meers | Zendy; Mary E. Neville | Zendy; Vladimir Malinin | Zendy; Aitana Scotto | Zendy; G. Sardaryan | Zendy; R. Kurumunda | Zendy; C. Mackinson | Zendy; Garth A. James | Zendy; Steven A. Fisher | Zendy; Walter R. Perkins | Zendy

Open Access

Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections

Author(s) -

Paul Meers,

Mary E. Neville,

Vladimir Malinin,

Aitana Scotto,

G. Sardaryan,

R. Kurumunda,

C. Mackinson,

Garth A. James,

Steven A. Fisher,

Walter R. Perkins

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn059

Subject(s) - amikacin , pseudomonas aeruginosa , microbiology and biotechnology , liposome , biofilm , in vivo , sputum , antimicrobial , pharmacology , chemistry , medicine , biology , bacteria , pathology , biochemistry , tuberculosis , genetics

Chronic infections of Pseudomonas aeruginosa in the lungs of cystic fibrosis patients are intractable antibiotic targets because of their biofilm mode of growth. We have investigated the biofilm penetration, mechanism of drug release and in vivo antimicrobial activity of a unique nanoscale liposomal formulation of amikacin designed specifically for nebulization and inhaled delivery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research